Therefore, although there are several studies reporting a tumour-suppressive effect of FGFR2 in a variety of cancer types, including bladder, prostate and skin (Feng et al., 1997; Grose and Dickson, 2005; Grose et al., 2007; Ricol et al., 1999; Zhang et al., 2001), it is easy to see how the pathway might be hijacked by cancer cells to provide them with a significant growth advantage. This evidence concerns the gene FGFR2 and neoplasm.